Differentiating scirrhous hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma based on Gd-EOB-DTPA-enhanced MRI and serum biomarkers in an HBV-positive high-risk cohort: a multi-center study
European Radiology · 20.07.2026
DOI: 10.1007/s00330-026-12749-4 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Radiology, online erschienen am 20.07.2026. Verfasst von Haoran He und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China. Die Arbeit nennt 23 Literaturangaben.
Abstract (Originalsprache)
Purpose
This study aimed to differentiate scirrhous hepatocellular carcinoma (SHCC) from intrahepatic mass-forming cholangiocarcinoma (IMCC) in HBV-infected patients using Gd-EOB-DTPA-enhanced MR imaging features combined with clinical variables. Materials and methods Sixty-three pathologically confirmed SHCC and 120 IMCC were analyzed retrospectively in HBV-infected patients admitted to three centers (118 patients from Center 1 for training and 65 patients from the other two centers for external validation). Clinicopathological characteristics and Gd-EOB-DTPA-enhanced MR imaging features were evaluated. Independent diagnostic factors for SHCC were identified using multivariate logistic regression. A preoperative diagnostic model combining these features with clinical variables was constructed, and its performance was assessed using receiver operating characteristic (ROC) curve analysis and decision curve analysis (DCA).
Results
Compared to IMCC, SHCC demonstrated a significantly lower incidence of necrosis (training: p = 0.03; validation: p = 0.002). A multivariable diagnostic model incorporating non-thin rim enhancement in the arterial phase, enhancing capsule, and signal loss on opposed-phase T1-weighted imaging, and relevant serum biomarkers achieved an area under the curve (AUC) of 0.951 (sensitivity 85.9%, specificity 88.4%). External validation yielded an AUC of 0.939 (sensitivity 85.0%, specificity 88.9%). DCA further confirmed its clinical utility, demonstrating positive net benefit across a range of threshold probabilities.
Conclusion
Non-thin rim enhancement in the arterial phase, enhancing capsule, and signal loss on opposed-phase T1-weighted imaging on Gd-EOB-DTPA-enhanced MRI, combined with related serum biomarkers, may differentiate SHCC from IMCC in HBV-infected patients with high accuracy. Key Points Question A reliable diagnostic approach that integrates Gd-EOB-DTPA-enhanced MRI features with serum biomarkers for differentiating SHCC from IMCC in HBV-infected patients has not been clearly defined .
Findings
A model integrating non-thin rim enhancement, enhancing capsule, opposed-phase signal loss, and related serum biomarkers effectively differentiated SHCC from IMCC in HBV-infected patients . Clinical relevance This study provides clinicians with a high-accuracy diagnostic model for differentiating SHCC from IMCC in the specific high-risk cohort, which may facilitate the development of personalized treatment plans and improvement of prognosis . Graphical Abstract
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Radiology, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, China.
- Department of Pathology, The First Affiliated Hospital of Soochow University, Suzhou, China.
- Department of Radiology, The Fourth Affiliated Hospital of Soochow University, Suzhou, China. zwg7807@suda.edu.cn.
- Department of Radiology, The First Affiliated Hospital of Soochow University, Suzhou, China. zwg7807@suda.edu.cn.
Zitieren
APA
He, H., Qiu, L., Song, M., Tao, Y., Zhang, H., Hu, X., Du, M., Guo, L., Hu, C., Shen, J., & Zhang, W. (2026). Differentiating scirrhous hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma based on Gd-EOB-DTPA-enhanced MRI and serum biomarkers in an HBV-positive high-risk cohort: a multi-center study. European Radiology. https://doi.org/10.1007/s00330-026-12749-4
Vancouver
He H, Qiu L, Song M, Tao Y, Zhang H, Hu X, et al. Differentiating scirrhous hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma based on Gd-EOB-DTPA-enhanced MRI and serum biomarkers in an HBV-positive high-risk cohort: a multi-center study. European Radiology. 2026. doi:10.1007/s00330-026-12749-4
BibTeX
@article{He2026,
author = {He, Haoran and Qiu, Leixin and Song, Mingyue and Tao, Yuhao and Zhang, Hanjun and Hu, Xin and Du, Mingzhan and Guo, Lingchuan and Hu, Chunhong and Shen, Jingxian and Zhang, Weiguo},
title = {Differentiating scirrhous hepatocellular carcinoma from intrahepatic mass-forming cholangiocarcinoma based on Gd-EOB-DTPA-enhanced MRI and serum biomarkers in an HBV-positive high-risk cohort: a multi-center study},
journal = {European Radiology},
year = {2026},
doi = {10.1007/s00330-026-12749-4}
}
EUVIMED